OTC, Supplement Co-Packaging Potential Could Be Clipped By FDA Proposed Rule
This article was originally published in The Pink Sheet
Executive Summary
Innovus Pharmaceuticals is among the firms offering supplements and OTC drugs sold together, an option CRN trade group encourages FDA to allow. FDA will determine on a case-by-case basis whether already available co-packaged OTCs and supplements violate a proposed rule on drug co-packaging.
You may also be interested in...
P&G Wraps Launch Of Super C Supplement Brand In Co-Packaging With DayQuil And NyQuil OTCs
P&G could be using a door left open in FDA’s 2015 proposed rule that questioned the safety of offering co-packaged supplements and drugs. With OTC drug and supplement firms always looking to drive sales growth, competitors large and small could follow P&G through the door.
Tech Transfer Roundup: Janssen, Eisai, Apexian, Innovus And More
Johnson & Johnson maintains hectic deal-making pace via RA tie-up with Monash and "diabesity" collaboration with UC San Diego.
Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product
FDA approves Hikma Pharmaceuticals subsidiary West-Ward Pharmaceuticals' ANDA for fluticasone propionate/0.05mg per spray and Perrigo is shipping the generic equivalent of Flonase Allergy Relief to retailers and distributors.